AMD: What’s in the Pipeline in 2023?
Provider: Mivision
Contact: Nikki Byrne, [E] nikki@mivision.com.au, [P] 02 8336 8616
Activity Outline
We are living in exciting times with regards to expanding treatment options for age-related macular degeneration (AMD). While we are all intimately familiar with the role that anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections play in the management of neovascular AMD (nAMD), we are on the cusp of realising other transformative therapeutic options for the subsets of the disease. In this article, Dr Amy Cohn highlights current research in the pipeline for macular disease treatments – some of which are closer than you think.
Learning Objectives
- Understand the current burdens of treatment associated with AMD, nAMD, and GA
- Be aware of therapeutic drugs in the pipeline for treatment of AMD, nAMD, and GA, and their proposed mechanism of action
- Be aware of gene therapies being explored for AMD, nAMD, and GA
Max CPD hours awarded: 1.25
Session Information
| Name |
|---|
| AMD: What’s in the Pipeline in 2023? |
| Clinical? |
| Yes |
| Interactive? |
| No |
| Therapeutic? |
| Yes |
| Duration of CPD Session/Module |
| 0.75 |
| Duration of CPD Session/Module inclusive of Assessment Component |
| 1.25 |